Review



sk mel 28  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC sk mel 28
    Sk Mel 28, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 34869 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk mel 28/product/ATCC
    Average 99 stars, based on 34869 article reviews
    sk mel 28 - by Bioz Stars, 2026-05
    99/100 stars

    Images



    Similar Products

    99
    ATCC sk mel 28
    Sk Mel 28, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk mel 28/product/ATCC
    Average 99 stars, based on 1 article reviews
    sk mel 28 - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    95
    ATCC sk mel 24 melanoma cell lines
    Sk Mel 24 Melanoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk mel 24 melanoma cell lines/product/ATCC
    Average 95 stars, based on 1 article reviews
    sk mel 24 melanoma cell lines - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    95
    ATCC sk mel 103
    Sk Mel 103, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk mel 103/product/ATCC
    Average 95 stars, based on 1 article reviews
    sk mel 103 - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    95
    ATCC sk mel 3
    Sk Mel 3, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sk mel 3/product/ATCC
    Average 95 stars, based on 1 article reviews
    sk mel 3 - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    htb  (ATCC)
    99
    ATCC htb
    Htb, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/htb/product/ATCC
    Average 99 stars, based on 1 article reviews
    htb - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC skmel28
    Transformation-induced changes to the protein composition of cell-derived sEVs (A) The morphology of isolated sEVs was assessed using transmission electron microscopy. Images of normal and transformed HBEC-derived sEVs (scale bars, 200 nm). (B) Nanoparticle analysis using tunable resistive pulse sensing of sEVs isolated from HBECs demonstrates that the majority of sEVs have a size range between 30 and 150 nm, and that transformation does not result in an increase in sEV secretion. (C) Western blot of sEVs from HBECs demonstrating the presence of sEV proteins HSP70 and CD63 and the absence of the cell marker calnexin. (D) Label-free mass spectrometry identified 148 proteins with greater abundance in sEVs derived from transformed HBECs (FDR <0.02), of which 15 were annotated as extracellular proteins. (E) Mass spectrometry results were confirmed using ELISA for THBS1, NID1, PTX3, and VCAN in sEVs derived from normal and transformed HBECs. (F) sEVs derived from 22 cancer cell lines including NSCLC (SKMES1, H1650, HCC4006, and H2170), glioblastoma ([GBM], D54, D270, U87, and U118), colorectal cancer ([CRC], HT29 and SW620), breast cancer ([BCa], BT549, MDA231, and MDA436), prostate cancer ([PCa], PC3 and LNCaP), melanoma ([MEL], A375, MAMEL65, and <t>SKMEL28),</t> esophageal cancer ([ECa], OE19), and ovarian cancer ([OVA], A2780, CAOV3, IGROV1, and OVCAR8) showed a clear increase in expression of THBS1, NID1, PTX3, and VCAN in relation to the average levels of sEVs from normal cells ([HBEC] 30KT, HOSE 6.3, and HOSE 17.1). Samples in mass spectrometry and ELISA were measured in triplicate. See also and .
    Skmel28, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/skmel28/product/ATCC
    Average 99 stars, based on 1 article reviews
    skmel28 - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC skmel28 human
    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from <t>SKMEL28</t> and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.
    Skmel28 Human, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/skmel28 human/product/ATCC
    Average 99 stars, based on 1 article reviews
    skmel28 human - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    Image Search Results


    Transformation-induced changes to the protein composition of cell-derived sEVs (A) The morphology of isolated sEVs was assessed using transmission electron microscopy. Images of normal and transformed HBEC-derived sEVs (scale bars, 200 nm). (B) Nanoparticle analysis using tunable resistive pulse sensing of sEVs isolated from HBECs demonstrates that the majority of sEVs have a size range between 30 and 150 nm, and that transformation does not result in an increase in sEV secretion. (C) Western blot of sEVs from HBECs demonstrating the presence of sEV proteins HSP70 and CD63 and the absence of the cell marker calnexin. (D) Label-free mass spectrometry identified 148 proteins with greater abundance in sEVs derived from transformed HBECs (FDR <0.02), of which 15 were annotated as extracellular proteins. (E) Mass spectrometry results were confirmed using ELISA for THBS1, NID1, PTX3, and VCAN in sEVs derived from normal and transformed HBECs. (F) sEVs derived from 22 cancer cell lines including NSCLC (SKMES1, H1650, HCC4006, and H2170), glioblastoma ([GBM], D54, D270, U87, and U118), colorectal cancer ([CRC], HT29 and SW620), breast cancer ([BCa], BT549, MDA231, and MDA436), prostate cancer ([PCa], PC3 and LNCaP), melanoma ([MEL], A375, MAMEL65, and SKMEL28), esophageal cancer ([ECa], OE19), and ovarian cancer ([OVA], A2780, CAOV3, IGROV1, and OVCAR8) showed a clear increase in expression of THBS1, NID1, PTX3, and VCAN in relation to the average levels of sEVs from normal cells ([HBEC] 30KT, HOSE 6.3, and HOSE 17.1). Samples in mass spectrometry and ELISA were measured in triplicate. See also and .

    Journal: Cell Reports Medicine

    Article Title: Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature

    doi: 10.1016/j.xcrm.2026.102694

    Figure Lengend Snippet: Transformation-induced changes to the protein composition of cell-derived sEVs (A) The morphology of isolated sEVs was assessed using transmission electron microscopy. Images of normal and transformed HBEC-derived sEVs (scale bars, 200 nm). (B) Nanoparticle analysis using tunable resistive pulse sensing of sEVs isolated from HBECs demonstrates that the majority of sEVs have a size range between 30 and 150 nm, and that transformation does not result in an increase in sEV secretion. (C) Western blot of sEVs from HBECs demonstrating the presence of sEV proteins HSP70 and CD63 and the absence of the cell marker calnexin. (D) Label-free mass spectrometry identified 148 proteins with greater abundance in sEVs derived from transformed HBECs (FDR <0.02), of which 15 were annotated as extracellular proteins. (E) Mass spectrometry results were confirmed using ELISA for THBS1, NID1, PTX3, and VCAN in sEVs derived from normal and transformed HBECs. (F) sEVs derived from 22 cancer cell lines including NSCLC (SKMES1, H1650, HCC4006, and H2170), glioblastoma ([GBM], D54, D270, U87, and U118), colorectal cancer ([CRC], HT29 and SW620), breast cancer ([BCa], BT549, MDA231, and MDA436), prostate cancer ([PCa], PC3 and LNCaP), melanoma ([MEL], A375, MAMEL65, and SKMEL28), esophageal cancer ([ECa], OE19), and ovarian cancer ([OVA], A2780, CAOV3, IGROV1, and OVCAR8) showed a clear increase in expression of THBS1, NID1, PTX3, and VCAN in relation to the average levels of sEVs from normal cells ([HBEC] 30KT, HOSE 6.3, and HOSE 17.1). Samples in mass spectrometry and ELISA were measured in triplicate. See also and .

    Article Snippet: SKMEL28 , ATCC , HTB-72; RRID: CVCL_0526.

    Techniques: Transformation Assay, Derivative Assay, Isolation, Transmission Assay, Electron Microscopy, Tunable Resistive Pulse Sensing, Western Blot, Marker, Mass Spectrometry, Enzyme-linked Immunosorbent Assay, Expressing

    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from SKMEL28 and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.

    Journal: Antibodies

    Article Title: A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAF V600E -Associated Mitochondrial Division in Cancer

    doi: 10.3390/antib15020038

    Figure Lengend Snippet: Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from SKMEL28 and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.

    Article Snippet: A375 and SKMEL28 human-derived non-primary (i.e., lymph node and secondary metastasis-derived, respectively) melanoma lines were purchased from ATCC and cultured in DMEM media.

    Techniques: Recombinant, Generated, Western Blot, Membrane, Isolation, Molecular Weight, Expressing, Quantitative RT-PCR, Knockdown, SDS Page, Phospho-proteomics, Control

    Oncogenic MAPK-regulated DRP1-S616Ⓟ expression is detected by recombinant 3G11. ( A ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green; mitochondria) and Hoechst 33342 (blue; nuclei). Scale bars = 10 microns. ( B ) SKMEL28 cells were studied as in ( A ). Mitochondrial networks are shown as maximum intensity projections of super-resolution Leica LIGHTNING deconvolved confocal z-stacks. Imaris surface features were used to generate 3D projections to visualize changes in mitochondrial network architecture. Scales bars = 5 microns. ( C ) Mitochondrial elongation was quantified using the Perimeter: Area Ratio. ( D , E ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green), DRP1-S616Ⓟ (red), and Hoechst 33342 (blue). Red channel intensity was quantified to assess DRP1-S616Ⓟ signal intensity using Mander’s coefficient. Scale bars = 10 microns. Zoomed network images (white dashed box) = 50 micron scale bars. ( F , G ) A375 cells were analyzed as panels ( D , E ). All experiments were performed at least twice, with statistical significance determined from a minimum of two independent experiments using a one-way ANOVA test. ** refers to a p value ≤ 0.01 and **** refers to a p value ≤ 0.0001.

    Journal: Antibodies

    Article Title: A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAF V600E -Associated Mitochondrial Division in Cancer

    doi: 10.3390/antib15020038

    Figure Lengend Snippet: Oncogenic MAPK-regulated DRP1-S616Ⓟ expression is detected by recombinant 3G11. ( A ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green; mitochondria) and Hoechst 33342 (blue; nuclei). Scale bars = 10 microns. ( B ) SKMEL28 cells were studied as in ( A ). Mitochondrial networks are shown as maximum intensity projections of super-resolution Leica LIGHTNING deconvolved confocal z-stacks. Imaris surface features were used to generate 3D projections to visualize changes in mitochondrial network architecture. Scales bars = 5 microns. ( C ) Mitochondrial elongation was quantified using the Perimeter: Area Ratio. ( D , E ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green), DRP1-S616Ⓟ (red), and Hoechst 33342 (blue). Red channel intensity was quantified to assess DRP1-S616Ⓟ signal intensity using Mander’s coefficient. Scale bars = 10 microns. Zoomed network images (white dashed box) = 50 micron scale bars. ( F , G ) A375 cells were analyzed as panels ( D , E ). All experiments were performed at least twice, with statistical significance determined from a minimum of two independent experiments using a one-way ANOVA test. ** refers to a p value ≤ 0.01 and **** refers to a p value ≤ 0.0001.

    Article Snippet: A375 and SKMEL28 human-derived non-primary (i.e., lymph node and secondary metastasis-derived, respectively) melanoma lines were purchased from ATCC and cultured in DMEM media.

    Techniques: Expressing, Recombinant, Staining